Lancet: Study on the effectiveness of the plant-based 4-price influenza vaccine.

Seasonal influenza remains a huge public health threat, especially as egg embryo vaccines are resisted by certain religious groups, and researchers recently examined the clinical effectiveness of the plant-based recombination of tylpical virus-like particles (QVLP) influenza vaccines.
The study was divided into two groups of adults aged 18-64, Queue 2 was conducted in 73 locations for groups aged 65 and over, and 104 locations in Asia, Europe and North America for groups over 65.
the 18-64-year-old study group was included with a BMI of less than 40 kg/m2;
the inclusion criteria for sub-groups over 65 years of age are a maximum BPI of 35 kg/m2, age 65 or above at the time of screening, no rehabilitation centre or nursing home care, no acute or progressive diseases.
the 18-64-year-old study received the QVLP vaccine (30 μg of hemocoagulant per strain) or a placebo at random.
the study group over 65 years of age were randomly vaccinated against the QVLP vaccine (30 μg of hemocoagulants per strain) or the four-price inactivated vaccine (QIV; 15?g of hemocoagulants per strain).
in the 18-64-year-olds study group, the main endpoint was the absolute effectiveness of the vaccine in preventing respiratory diseases caused by laboratory-confirmed, antigen-matched influenza strains.
result of the study group over 65 years of age is the relative effectiveness of vaccine prevention laboratory-confirmed influenza-like diseases caused by any influenza strain.
10,160 participants in the 18-64-year-old study group, including 5,077 participants in the QVLP vaccine group and 5,083 participants in the placebo group.
the study, there were 4,814 participants in the QVLP group and 4,812 participants in the placebo group who were included in the endpoint analysis.
the absolute effectiveness of the QVLP vaccine was 35.1% and did not reach the main endpoint of 70%.
QVLP group had severe adverse events in 55 patients (1.1%) and 51 (1.0%) patients in the placebo group had severe adverse events, with 4 (0.1%) and 6 (0.1%) participants having serious treatment-related adverse events, respectively.
12,794 participants in the study over the age of 65 were included in the endpoint analysis of 6,396 participants in the QVLP vaccine group, 6,398 participants in the QIVV group, 5,996 participants in the QVLP group and 6,026 participants in the QIV group.
study was consistent with its main non-poor end point, with an 8.8% difference in the relative effectiveness of the QVLP vaccine in preventing any flu-like disease compared to QIV.
263 (4.1%) of the 6,352 participants in the QVLP group had serious adverse events, while 266 (4.2%) of the 6366 participants in the QIV group had serious adverse events.
study concluded that the plant-based four-price flu vaccine has the same effect on the prevention of influenza-like diseases in the 65-year-old population as the four-price inactivated vaccine, and has good tolerance.
.